NCT02703636 - NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients. | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

May 7, 2018

Study Completion Date

May 7, 2018

Conditions

Mild to Moderate Alzheimer's Disease

Interventions

DRUG

Rivastigmine Patch

Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.

Trial Locations (19)

814 0180

Novartis Investigative Site, Fukuoka

814-0015

Novartis Investigative Site, Fukuoka

965-8585

Novartis Investigative Site, Aizu-Wakamatsu

305-8576

Novartis Investigative Site, Tsukuba

761-0793

Novartis Investigative Site, Kita-gun

252-5188

Novartis Investigative Site, Sagamihara

780-0842

Novartis Investigative Site, Kochi

955-0823

Novartis Investigative Site, Sanjō

710-0826

Novartis Investigative Site, Kurashiki

543-8555

Novartis Investigative Site, Osaka

565 0871

Novartis Investigative Site, Suita

344-0036

Novartis Investigative Site, Kasukabe

343-0032

Novartis Investigative Site, Koshigaya

416-0955

Novartis Investigative Site, Fuji

113-8431

Novartis Investigative Site, Bunkyo Ku

193-0944

Novartis Investigative Site, Hachiōji

160-0023

Novartis Investigative Site, Shinjuku-ku

168-8535

Novartis Investigative Site, Suginami Ku

710-0813

Novartis Investigative Site, Okayama